Drug
Vk0214
Vk0214: highest development phase Phase 1, developed by Viking Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Viking Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VK0214 NCT04973657 | Phase 1 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) |
Latest
No recent events.
Follow Vk0214 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.